Altimmune, Inc., (ticker symbol: ALT) is a pioneering American biotechnology company. Founded in 1997 and headquartered in Gaithersburg, Maryland, Altimmune is focused on the development of vaccines and immune modulating therapies. Over the years, the company has been dedicated in the field of life sciences, endeavoring to provide solutions to treat diseases and improve public health.
Altimmune is principle to the research and clinical developments in the pharmaceutical sector. The company's product portfolio is widespread, covering treatments for nasally administered immune-modulating therapies and respiratory infections. These products are in various phases of clinical trials with the aim to treat acute illnesses to chronic diseases. One of the standout products of Altimmune is the intranasal Covid-19 vaccine, currently in the developing stages. The company is also currently involved in creating vaccines for Hepatitis B and anthrax.
The company’s research and developments go beyond the boundaries of traditional vaccines and include cutting-edge immune modulating products. Altimmune’s therapies are structured in a way to guide the immune system to act against diseases. Its platform, RespirVec, is a unique technology that allows vaccines to be administered through nasal route, enhancing the systemic and respiratory tract immunity.
Parallel to its operations in the United States, Altimmune also has an office in the United Kingdom, thus making them a player in the global pharmaceutical industry. The company is run by a team of highly experienced professionals who lead the entity towards innovation, integrity, and partnerships.
Being a listed company in the stock market, under the Nasdaq Capital Market, Altimmune has a transparent and law-governed financial practice. The stock performance of the company (ALT) has attracted investors interested in the biopharmaceutical sector.
In a nutshell, Altimmune, Inc., is a pharmaceutical torchbearer with a commitment to medical advancement and enhancing human wellbeing. The company is focused on the development of treatments for an array of diseases, extending from acute respiratory infections to chronic liver diseases. The company is uniquely positioned in the biotechnology industry, tackling global threats like the Covid-19 pandemic and other detrimental diseases. With further research underway, the world can look to Altimmune for groundbreaking developments in the vaccine stratosphere.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Altimmune, Inc. announced its management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026, at 10:30 a.m. ET. The company, a late clinical-stage biopharmaceutical firm, is developing pemvidutide for serious liver diseases, including MASH, AUD, and ALD. A webcast of the chat will be available on Altimmune's website.
Altimmune (ALT) shares have risen 14.2% since its last earnings report, outperforming the S&P 500. The company reported a narrower-than-expected Q2 2026 loss of 12 cents per share, with no revenues as it lacks a marketed drug. R&D expenses increased due to clinical studies for pemvidutide, and the company expects its cash runway to last until 2029.
Altimmune (NASDAQ:ALT) shares rose 9.2% on Friday, closing at $3.22, although trading volume was significantly lower than average. Analyst sentiment is generally positive, with a "Moderate Buy" consensus and a $14.33 average price target. Despite beating quarterly loss estimates, the clinical-stage biopharmaceutical company continues to face deeply negative profitability metrics, with institutional investors holding 78.05% of its stock.
HC Wainwright has revised its Q3 2026 earnings per share estimates for Altimmune (NASDAQ:ALT) to a loss of $0.13, an improvement from its prior estimate of $0.15. The firm also updated its full-year and multi-year forecasts, expecting the company to remain unprofitable through 2030, though with reduced projected losses. Altimmune recently surpassed consensus estimates for its latest quarter, reporting a loss of $0.12 per share against an expected $0.14 loss.